HVTN 405/HPTN 1901 will describe immune responses in study participants with a history of recovering from SARS- CoV-2 infection. A main aim of HVTN 405/HPTN 1901 is to develop antibody assays that can be reliably used to detect SARS-CoV-2 infection in vaccine and monoclonal antibody studies to prevent COVID-19. This information will be critical in illuminating the path to the development and testing of safe and effective vaccine and antibody interventions to prevent COVID-19.
How will study participants contribute to HVTN 405/HPTN 1901?
Participants will attend one required clinic visit and will have the option to attend additional clinic visits two, four and twelve months after the initial visit.
Each visit includes a questionnaire, blood draw and optional nasal sampling.
Individuals who have not fully recovered from their infection (i.e., still have symptoms or had a positive test within the preceding two weeks) will not be enrolled.